Efficacy appears to hinge on product quality: Chandran showed higher frequencies of autologous tumor-reactive T cells and greater IFN-γ release in responders, while Murali’s Uveal Melanoma Immunogenomic Score (UMIS) identifies metastases harboring potent but quiescent TILs and predicts benefit after adoptive transfer. Here, IFNG is linked to melanoma.